Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS) and various types of cancer, today announces that the Company is now trading on the OTCQX marketplace under the Company’s existing stock ticker AVXL. OTCQX is the best marketplace for established, global and growth companies operated by OTC Markets Group Inc.
To qualify for trading on OTCQX, companies must meet high financial standards, demonstrate compliance with U.S. securities laws, be current in their disclosure, and be sponsored by a professional third-party advisor. Fewer than 400 companies are currently trading on the OTCQX and they range from global blue-chip companies to high-growth small caps.
“Anavex is pleased to be joining the top-tier firms trading on the OTCQX. This is another important step for our Company as we advance ANAVEX 2-73 and ANAVEX PLUS in the clinic and move forward with our pipeline of promising compounds,” said Christopher U. Missling, PhD, President and Chief Executive Officer for Anavex. “We also expect the potential of improved visibility and liquidity of our stock to contribute to long-term shareholder value.”
“We are pleased to welcome Anavex to the OTCQX marketplace,” said R. Cromwell Coulson, President and CEO of OTC Markets Group. “Growing U.S. companies like Anavex choose OTCQX to demonstrate transparency and increase their visibility and engagement with U.S. investors. We look forward to working with Anavex’s management team as the company continues to grow and expand its presence in the U.S. market.”
U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for Anavex on www.otcmarkets.com.